.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Post-Conference Perspectives: Optimizing the Management of HER2+ Metastatic Breast Cancer

EP. 1: HER2+ Metastatic Breast Cancer: Standard of Care Therapies

December 24th 2019

EP. 2: Management of CNS Metastases in R/R HER2+ mBC

December 24th 2019

EP. 3: HER2+ mBC: Systemic Therapies and HER2CLIMB-02 Trial

December 24th 2019

EP. 4: Emerging Data for the Treatment of HER2+ mBC

December 24th 2019

EP. 5: HER2+ Breast Cancer: Brain Metastasis Prevalence & Later-Line Therapy

December 24th 2019

EP. 6: The HER2CLIMB-02 Trial Design, Results and Implications

December 24th 2019

EP. 7: HER2CLIMB-02 Trial Regimen Toxicities and Impact

December 24th 2019

EP. 8: Current Advancements in HER2+ Breast Cancer Management

December 24th 2019